

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013

PART I

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Twelve Months ended	
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012
		(Refer Note No. 4 )	Unaudited	(Refer Note No. 4 )	Audited	Audited
1	<b>Income from Operations</b>					
	a) Net Sales/Income from Operations	15,074.86	16,134.99	20,354.83	71,806.95	83,477.42
	b) Other Operating Income	52.98	111.36	56.75	426.05	702.31
	<b>c) Total Income from Operations</b>	<b>15,127.84</b>	<b>16,246.35</b>	<b>20,411.58</b>	<b>72,233.00</b>	<b>84,179.73</b>
2	<b>Expenses</b>					
	a) Cost of materials consumed	9,342.57	8,049.25	19,210.08	48,434.51	61,445.02
	b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	893.26	2,954.81	(5,081.70)	2,749.80	(3,350.82)
	d) Employee benefits expense	1,367.37	1,334.53	1,327.83	5,467.68	5,368.03
	e) Depreciation and amortization expense	6,443.62	6,334.62	6,785.71	25,431.66	26,004.96
	f) Other Expenses	1,236.76	1,185.64	1,348.47	5,686.91	5,255.12
	<b>g) Total Expenses</b>	<b>19,283.58</b>	<b>19,858.85</b>	<b>23,590.39</b>	<b>87,770.56</b>	<b>94,722.31</b>
3	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(4,155.74)</b>	<b>(3,612.50)</b>	<b>(3,178.81)</b>	<b>(15,537.56)</b>	<b>(10,542.58)</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(4,155.74)</b>	<b>(3,612.50)</b>	<b>(3,178.81)</b>	<b>(15,537.56)</b>	<b>(10,542.58)</b>
6	Finance Costs	11,533.39	11,098.48	10,299.88	43,770.79	41,232.82
7	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(15,689.13)</b>	<b>(14,710.98)</b>	<b>(13,478.69)</b>	<b>(59,308.35)</b>	<b>(51,775.40)</b>
8	Tax expense					
	a) Current	0.00	0.00	0.00	0.00	0.00
	b) Deferred	(5,090.00)	(4,773.00)	(4,373.00)	(19,243.00)	(16,798.00)
	<b>c) Total</b>	<b>(5,090.00)</b>	<b>(4,773.00)</b>	<b>(4,373.00)</b>	<b>(19,243.00)</b>	<b>(16,798.00)</b>
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(10,599.13)</b>	<b>(9,937.98)</b>	<b>(9,105.69)</b>	<b>(40,065.35)</b>	<b>(34,977.40)</b>
10	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(10,599.13)</b>	<b>(9,937.98)</b>	<b>(9,105.69)</b>	<b>(40,065.35)</b>	<b>(34,977.40)</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	0.00
13	<b>Profit available for appropriation</b>	<b>(10,599.13)</b>	<b>(9,937.98)</b>	<b>(9,105.69)</b>	<b>(40,065.35)</b>	<b>(34,977.40)</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet				144,333.65	184,399.00
16.i	Earnings Per Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)					
	a) Basic	(3.96)	(3.71)	(3.40)	(14.96)	(13.06)
	b) Diluted	(3.50)	(3.29)	(3.01)	(13.24)	(11.56)
16.ii	Earnings Per Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)					
	a) Basic	(3.96)	(3.71)	(3.40)	(14.96)	(13.06)
	b) Diluted	(3.50)	(3.29)	(3.01)	(13.24)	(11.56)

**STERLING BIOTECH LIMITED**  
Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

Select Information for the Year ended 31 December 2013

**PART II**

Sr. No.	Particulars	Three Months ended			Twelve Months ended	
		31/12/2013	30/09/2013	31/12/2012	31/12/2013	31/12/2012
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding					
	- Number of shares	131,861,090	131,861,090	131,861,090	131,861,090	131,861,090
	- Percentage of shareholding	49.23%	49.23%	49.23%	49.23%	49.23%
2	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	18.97%	18.97%	18.97%	18.97%
	b) Non-encumbered					
	Number of shares	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	14.94%	14.94%	14.94%	14.94%

Sr. No.	Particulars	Quarter ended 31/12/2013
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

**STANDALONE STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lacs)

Sr. No.	Particulars	STANDALONE	
		Twelve Months Ended	
		31/12/2013	31/12/2012
		Audited	Audited
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>SHAREHOLDERS' FUND</b>		
	a) Share Capital	2,678.74	2,678.74
	b) Reserves and Surplus	144,333.65	184,399.00
	c) Money received against share warrants	0.00	0.00
	<b>Sub - total Shareholders' Funds</b>	<b>147,012.39</b>	<b>187,077.74</b>
2	Share Application money pending allotment	0.00	0.00
3	<b>Non-current liabilities</b>		
	a) Long-term borrowings	94,778.49	113,734.94
	b) Deferred tax liabilities (net)	0.00	14,684.01
	c) Other long-term liabilities	0.00	0.00
	d) Long-term provisions	0.00	0.00
	<b>Sub-total - Non-current liabilities</b>	<b>94,778.49</b>	<b>128,418.95</b>
4	<b>Current liabilities</b>		
	a) Short-term borrowings	169,252.24	147,178.97
	b) Trade payables	2,005.17	2,649.89
	c) Other current liabilities	326,834.44	243,042.27
	d) Short-term provisions	0.00	0.00
	<b>Sub-total - Current liabilities</b>	<b>498,091.85</b>	<b>392,871.13</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>739,882.73</b>	<b>708,367.82</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	a) Fixed assets	554,322.78	518,494.32
	b) Goodwill on consolidation	0.00	0.00
	c) Non-current investments	37,651.74	37,651.75
	d) Deferred tax assets (net)	4,558.99	0.00
	e) Long-term loans and advances	0.00	0.00
	f) Other non-current assets	0.00	0.00
	<b>Sub-total - Non-current assets</b>	<b>596,533.51</b>	<b>556,146.07</b>
2	<b>Current assets</b>		
	a) Current investments	0.00	0.00
	b) Inventories	79,351.98	86,993.74
	c) Trade receivables	33,570.60	34,709.60
	d) Cash and cash equivalents	1,748.72	1,783.30
	e) Short-term loans and advances	28,677.92	28,735.11
	f) Other current assets	0.00	0.00
	<b>Sub-total - Current assets</b>	<b>143,349.22</b>	<b>152,221.75</b>
	<b>TOTAL - ASSETS</b>	<b>739,882.73</b>	<b>708,367.82</b>

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2013**

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and approved by the Board of Directors in its meeting held on 28 February 2014 and have been Audited by the Statutory Auditors of the Company.
- 3 The Company has Overseas Subsidiary and there are no business operations in the subsidiary company.
- 4 The Figures of the last Quarter ended on 31 December 2013 are the Balancing figures between the audited figures in respect of the full financial year ended on 31 December 2013 and published year to date figures upto the third quarter ended on 30 September 2013 of the Current year and figures for corresponding Quarter ended on 31 December 2012 are the Balancing figures between the audited figures in respect of the full financial year ended on 31 December 2012 and published year to date figures upto the third quarter ended on 30 September 2012.
- 5 The Board has not recommended any dividend on equity shares for the financial year ended 31st December, 2013.
- 6 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 28 February 2014.

**Chetan J. Sandesara  
Joint Managing Director**